Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Biotechnology

Editor-in-Chief

ISSN (Print): 1389-2010
ISSN (Online): 1873-4316

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Mini-Review Article

Novel Therapeutic Approaches and Targets for Treatment of Chronic Urticaria: New Insights and Promising Targets for a Challenging Disease

Author(s): Emanuela Martina*, Federico Diotallevi, Tommaso Bianchelli, Matteo Paolinelli and Annamaria Offidani

Volume 22, Issue 1, 2021

Published on: 30 June, 2020

Page: [32 - 45] Pages: 14

DOI: 10.2174/1389201021666200630140137

Price: $65

Abstract

Background: Chronic Spontaneous Urticaria (CSU) is a disease characterized by the onset of wheals and/or angioedema over 6 weeks. The pathophysiology for CSU is very complex, involving mast cells and basophils with a multitude of inflammatory mediators. For many years the treatment of CSU has been based on the use of antihistamines, steroids and immunosuppressive agents with inconstant and frustrating results. The introduction of omalizumab, the only licensed biologic for antihistamine- refractory CSU, has changed the management of the disease.

Objective: The aim of this article is to review the current state of the art of CSU, the real-life experience with omalizumab and the promising drugs that are under development.

Methods: An electronic search was performed to identify studies, case reports, guidelines and reviews focused on the new targets for the treatment of chronic spontaneous urticaria, both approved or under investigation. The search was limited to articles published in peer-reviewed journals in the English Language in the PubMed database and trials registered in Clinicaltrials.gov.

Results: Since the advent of omalizumab, the search for new therapies for chronic spontaneous urticaria has had a new impulse. Anti-IgE drugs will probably still be the cornerstone of therapy, but new targets may prove effective in syndromic urticaria or refractory cases.

Conclusion: Although omalizumab has been a breakthrough in the treatment of CSU, many patients do not completely get benefit and even require more effective treatments. Novel drugs are under investigation with promising results.

Keywords: Urticaria, omalizumab, biologic drugs, target therapy, CSU, novel drugs.

« Previous Next »
Graphical Abstract

[1]
Zuberbier, T.; Aberer, W.; Asero, R.; Abdul Latiff, A.H.; Baker, D.; Ballmer-Weber, B.; Bernstein, J.A.; Bindslev-Jensen, C.; Brzoza, Z.; Bedrikow, B.R.; Canonica, G.W.; Church, M.K.; Craig, T.; Danilycheva, I.V.; Dressler, C.; Ensina, L.F.; Giménez-Arnau, A.; Godse, K.; Gonçalo, M.; Grattan, C.; Hebert, J.; Hide, M.; Kaplan, A.; Kapp, A.; Katelaris, C.H.; Kocatürk, E.; Kulthanan, K.; Larenas-Linnemann, D.; Leslie, T.A.; Magerl, M.; Mathelier-Fusade, P.; Meshkova, R.Y.; Metz, M.; Nast, A.; Nettis, E.; Oude-Elberink, H.; Rosumeck, S.; Saini, S.S.; Sánchez-Borges, M.; Schmid-Grendelmeier, P.; Staubach, P.; Sussman, G.; Toubi, E.; Vena, G.A.; Vestergaard, C.; Wedi, B.; Werner, R.N.; Zhao, Z.; Maurer, M. Endorsed by the following societies: AAAAI, AAD, AAIITO, ACAAI, AEDV, APAAACI, ASBAI, ASCIA, BAD, BSACI, CDA, CMICA, CSACI, DDG, DDS, DGAKI, DSA, DST, EAACI, EIAS, EDF, EMBRN, ESCD, GA2LEN, IAACI, IADVL, JDA, NVvA, MSAI, ÖGDV, PSA, RAACI, SBD, SFD, SGAI, SGDV, SIAAIC, SIDeMaST, SPDV, TSD, UNBB, UNEV and WAO. The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy, 2018, 73(7), 1393-1414.
[http://dx.doi.org/10.1111/all.13397] [PMID: 29336054]
[2]
Maurer, M.; Weller, K.; Bindslev-Jensen, C.; Giménez-Arnau, A.; Bousquet, P.J.; Bousquet, J.; Canonica, G.W.; Church, M.K.; Godse, K.V.; Grattan, C.E.; Greaves, M.W.; Hide, M.; Kalogeromitros, D.; Kaplan, A.P.; Saini, S.S.; Zhu, X.J.; Zuberbier, T. Unmet clinical needs in chronic spontaneous urticaria. A GA2LEN task force report. Allergy, 2011, 66(3), 317-330.
[http://dx.doi.org/10.1111/j.1398-9995.2010.02496.x] [PMID: 21083565]
[3]
Finlay, A.Y.; Kaplan, A.P.; Beck, L.A.; Antonova, E.N.; Balp, M.M.; Zazzali, J.; Khalil, S.; Maurer, M. Omalizumab substantially improves dermatology-related quality of life in patients with chronic spontaneous urticaria. J. Eur. Acad. Dermatol. Venereol., 2017, 31(10), 1715-1721.
[http://dx.doi.org/10.1111/jdv.14384] [PMID: 28573683]
[4]
Staubach, P.; Dechene, M.; Metz, M.; Magerl, M.; Siebenhaar, F.; Weller, K.; Zezula, P.; Eckhardt-Henn, A.; Maurer, M. High prevalence of mental disorders and emotional distress in patients with chronic spontaneous urticaria. Acta Derm. Venereol., 2011, 91(5), 557-561.
[http://dx.doi.org/10.2340/00015555-1109] [PMID: 21597672]
[5]
Chu, C.Y.; Cho, Y.T.; Jiang, J.H.; Chang, C.C.; Liao, S.C.; Tang, C.H. Patients with chronic urticaria have a higher risk of psychiatric disorders: a population-based study. Br. J. Dermatol., 2020, 182(2), 335-341.
[http://dx.doi.org/10.1111/bjd.18240] [PMID: 31220338]
[6]
Özkan, M.; Oflaz, S.B.; Kocaman, N.; Ozseker, F.; Gelincik, A.; Büyüköztürk, S.; Ozkan, S.; Colakoğlu, B. Psychiatric morbidity and quality of life in patients with chronic idiopathic urticaria. Ann. Allergy Asthma Immunol., 2007, 99(1), 29-33.
[http://dx.doi.org/10.1016/S1081-1206(10)60617-5] [PMID: 17650826]
[7]
Zuberbier, T.; Aberer, W.; Asero, R.; Bindslev-Jensen, C.; Brzoza, Z.; Canonica, G.W.; Church, M.K.; Ensina, L.F.; Giménez-Arnau, A.; Godse, K.; Gonçalo, M.; Grattan, C.; Hebert, J.; Hide, M.; Kaplan, A.; Kapp, A.; Abdul Latiff, A.H.; Mathelier-Fusade, P.; Metz, M.; Nast, A.; Saini, S.S.; Sánchez-Borges, M.; Schmid-Grendelmeier, P.; Simons, F.E.; Staubach, P.; Sussman, G.; Toubi, E.; Vena, G.A.; Wedi, B.; Zhu, X.J.; Maurer, M. European Academy of Allergy and Clinical Immunology; Global Allergy and Asthma European Network; European Dermatology Forum; World Allergy Organization. The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: The 2013 revision and update. Allergy, 2014, 69(7), 868-887.
[http://dx.doi.org/10.1111/all.12313] [PMID: 24785199]
[8]
Kaplan, A.P.; Horáková, Z.; Katz, S.I. Assessment of tissue fluid histamine levels in patients with urticaria. J. Allergy Clin. Immunol., 1978, 61(6), 350-354.
[http://dx.doi.org/10.1016/0091-6749(78)90113-6] [PMID: 659726]
[9]
Deza, G.; March-Rodríguez, A.; Sánchez, S.; Ribas-Llauradó, C.; Soto, D.; Pujol, R.M.; Gimeno, R.; Giménez-Arnau, A.M. Relevance of the basophil high-affinity ige receptor in chronic urticaria: Clinical experience from a tertiary care institution. J. Allergy Clin. Immunol. Pract., 2019, 7(5), 1619-1626.e1.
[http://dx.doi.org/10.1016/j.jaip.2019.01.026] [PMID: 30685572]
[10]
Concha, L.B.; Chang, C.C.; Szema, A.M.; Dattwyler, R.J.; Carlson, H.E. IgE antithyroid antibodies in patients with Hashimoto’s disease and chronic urticaria. Allergy Asthma Proc., 2004, 25(5), 293-296.
[PMID: 15603201]
[11]
Hide, M.; Francis, D.M.; Grattan, C.E.; Hakimi, J.; Kochan, J.P.; Greaves, M.W. Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria. N. Engl. J. Med., 1993, 328(22), 1599-1604.
[http://dx.doi.org/10.1056/NEJM199306033282204] [PMID: 7683772]
[12]
Kolkhir, P.; Church, M.K.; Weller, K.; Metz, M.; Schmetzer, O.; Maurer, M. Autoimmune chronic spontaneous urticaria: What we know and what we do not know. J. Allergy Clin. Immunol., 2017, 139(6), 1772-1781.e1.
[http://dx.doi.org/10.1016/j.jaci.2016.08.050] [PMID: 27777182]
[13]
Boelaert, K.; Newby, P.R.; Simmonds, M.J.; Holder, R.L.; Carr-Smith, J.D.; Heward, J.M.; Manji, N.; Allahabadia, A.; Armitage, M.; Chatterjee, K.V.; Lazarus, J.H.; Pearce, S.H.; Vaidya, B.; Gough, S.C.; Franklyn, J.A. Prevalence and relative risk of other autoimmune diseases in subjects with autoimmune thyroid disease. Am. J. Med., 2010, 123(2), 183.e1-183.e9.
[http://dx.doi.org/10.1016/j.amjmed.2009.06.030] [PMID: 20103030]
[14]
Bar-Sela, S.; Reshef, T.; Mekori, Y.A. IgE antithyroid microsomal antibodies in a patient with chronic urticaria. J. Allergy Clin. Immunol., 1999, 103(6), 1216-1217.
[http://dx.doi.org/10.1016/S0091-6749(99)70204-6] [PMID: 10359911]
[15]
Fusari, A.; Colangelo, C.; Bonifazi, F.; Antonicelli, L. The autologous serum skin test in the follow-up of patients with chronic urticaria. Allergy, 2005, 60(2), 256-258.
[http://dx.doi.org/10.1111/j.1398-9995.2005.00673.x] [PMID: 15647050]
[16]
Asero, R.; Tedeschi, A.; Riboldi, P.; Cugno, M. Plasma of patients with chronic urticaria shows signs of thrombin generation, and its intradermal injection causes wheal-and-flare reactions much more frequently than autologous serum. J. Allergy Clin. Immunol., 2006, 117(5), 1113-1117.
[http://dx.doi.org/10.1016/j.jaci.2005.12.1343] [PMID: 16675340]
[17]
Asero, R.; Tedeschi, A.; Coppola, R.; Griffini, S.; Paparella, P.; Riboldi, P.; Marzano, A.V.; Fanoni, D.; Cugno, M. Activation of the tissue factor pathway of blood coagulation in patients with chronic urticaria. J. Allergy Clin. Immunol., 2007, 119(3), 705-710.
[http://dx.doi.org/10.1016/j.jaci.2006.08.043] [PMID: 17204316]
[18]
Asero, R.; Tedeschi, A.; Riboldi, P.; Griffini, S.; Bonanni, E.; Cugno, M. Severe chronic urticaria is associated with elevated plasma levels of D-dimer. Allergy, 2008, 63(2), 176-180.
[PMID: 17961199]
[19]
Asero, R. D-dimer: A biomarker for antihistamine-resistant chronic urticaria. J. Allergy Clin. Immunol., 2013, 132(4), 983-986.
[http://dx.doi.org/10.1016/j.jaci.2013.04.037] [PMID: 23763979]
[20]
Fujii, K.; Usuki, A.; Kan-No, Y.; Ohgou, N. Elevation of circulating thrombin-antithrombin III complex and fibrin degradation products in urticaria: A laboratory finding unrelated to intravascular coagulopathy. J. Dermatol., 2008, 35(5), 308-310.
[http://dx.doi.org/10.1111/j.1346-8138.2008.00474.x] [PMID: 18477235]
[21]
Puxeddu, I.; Petrelli, F.; Angelotti, F.; Croia, C.; Migliorini, P. Biomarkers in chronic spontaneous urticaria: Current targets and clinical implications. J. Asthma Allergy, 2019, 12, 285-295.
[http://dx.doi.org/10.2147/JAA.S184986] [PMID: 31571935]
[22]
Kessel, A.; Helou, W.; Bamberger, E.; Sabo, E.; Nusem, D.; Panassof, J.; Toubi, E. Elevated serum total IgE--a potential marker for severe chronic urticaria. Int. Arch. Allergy Immunol., 2010, 153(3), 288-293.
[http://dx.doi.org/10.1159/000314370] [PMID: 20484928]
[23]
Straesser, M.D.; Oliver, E.; Palacios, T.; Kyin, T.; Patrie, J.; Borish, L.; Saini, S.S.; Lawrence, M.G. Serum IgE as an immunological marker to predict response to omalizumab treatment in symptomatic chronic urticaria. J. Allergy Clin. Immunol. Pract., 2018, 6(4), 1386-1388.e1.
[http://dx.doi.org/10.1016/j.jaip.2017.10.030] [PMID: 29175369]
[24]
Weller, K.; Ohanyan, T.; Hawro, T.; Ellrich, A.; Sussman, G.; Koplowitz, J.; Gimenez-Arnau, A.M.; Peveling-Oberhag, A.; Staubach, P.; Metz, M.; Maurer, M. Total IgE levels are linked to the response of chronic spontaneous urticaria patients to omalizumab. Allergy, 2018, 73(12), 2406-2408.
[http://dx.doi.org/10.1111/all.13586] [PMID: 30076605]
[25]
Kasperska-Zajac, A.; Grzanka, A.; Machura, E.; Misiolek, M.; Mazur, B.; Jochem, J. Increased serum complement C3 and C4 concentrations and their relation to severity of chronic spontaneous urticaria and CRP concentration. J. Inflamm. (Lond.), 2013, 10(1), 22.
[http://dx.doi.org/10.1186/1476-9255-10-22]
[26]
Kolkhir, P.; Altrichter, S.; Hawro, T.; Maurer, M. C-reactive protein is linked to disease activity, impact, and response to treatment in patients with chronic spontaneous urticarial. Allergy Eur. J. Allergy Clin. Immunol., 2018, 73(4), 940-948.
[http://dx.doi.org/10.1111/all.13352]
[27]
Ohtsuka, T. Response to oral cyclosporine therapy and high sensitivity-CRP level in chronic idiopathic urticaria. Int. J. Dermatol., 2010, 49(5), 579-584.
[http://dx.doi.org/10.1111/j.1365-4632.2010.04384.x] [PMID: 20534097]
[28]
Młynek, A.; Zalewska-Janowska, A.; Martus, P.; Staubach, P.; Zuberbier, T.; Maurer, M. How to assess disease activity in patients with chronic urticaria? Allergy, 2008, 63(6), 777-780.
[http://dx.doi.org/10.1111/j.1398-9995.2008.01726.x] [PMID: 18445192]
[29]
Hawro, T.; Ohanyan, T.; Schoepke, N.; Metz, M.; Peveling-Oberhag, A.; Staubach, P.; Maurer, M.; Weller, K. Comparison and interpretability of the available urticaria activity scores. Allergy, 2018, 73(1), 251-255.
[http://dx.doi.org/10.1111/all.13271] [PMID: 28815631]
[30]
Kowalski, M.L.; Woessner, K.; Sanak, M. Approaches to the diagnosis and management of patients with a history of nonsteroidal anti-inflammatory drug-related urticaria and angioedema. J. Allergy Clin. Immunol., 2015, 136(2), 245-251.
[http://dx.doi.org/10.1016/j.jaci.2015.06.021] [PMID: 26254051]
[31]
Shakouri, A.; Compalati, E.; Lang, D.M.; Khan, D.A. Effectiveness of Helicobacter pylori eradication in chronic urticaria: Evidence-based analysis using the grading of recommendations assessment, development, and evaluation system. Curr. Opin. Allergy Clin. Immunol., 2010, 10(4), 362-369.
[http://dx.doi.org/10.1097/ACI.0b013e32833c79d7] [PMID: 20610979]
[32]
Campanati, A.; Gesuita, R.; Giannoni, M.; Piraccini, F.; Sandroni, L.; Martina, E.; Conocchiari, L.; Bendia, E.; Di Sario, A.; Offidani, A. Role of small intestinal bacterial overgrowth and Helicobacter pylori infection in chronic spontaneous urticaria: A prospective analysis. Acta Derm. Venereol., 2013, 93(2), 161-164.
[http://dx.doi.org/10.2340/00015555-1373] [PMID: 22858910]
[33]
Ergon, M.C. iĺknur, T.; Yućesoy, M.; Oźkan, S. Candida spp. colonization and serum anticandidal antibody levels in patients with chronic urticaria. Clin. Exp. Dermatol., 2007, 32(6), 740-743.
[http://dx.doi.org/10.1111/j.1365-2230.2007.02512.x] [PMID: 17953642]
[34]
Akoglu, G.; Atakan, N.; Cakır, B.; Kalayci, O.; Hayran, M. Effects of low pseudoallergen diet on urticarial activity and leukotriene levels in chronic urticaria. Arch. Dermatol. Res., 2012, 304(4), 257-262.
[http://dx.doi.org/10.1007/s00403-011-1203-3] [PMID: 22200952]
[35]
Wagner, N.; Dirk, D.; Peveling-Oberhag, A.; Reese, I.; Rady-Pizarro, U.; Mitzel, H.; Staubach, P. A Popular myth - low-histamine diet improves chronic spontaneous urticaria - fact or fiction? J. Eur. Acad. Dermatol. Venereol., 2017, 31(4), 650-655.
[http://dx.doi.org/10.1111/jdv.13966] [PMID: 27624921]
[36]
Gimenez-Arnau, A.; Pujol, R.M.; Ianosi, S.; Kaszuba, A.; Malbran, A.; Poop, G.; Donado, E.; Perez, I.; Izquierdo, I.; Arnaiz, E. Rupatadine Urticaria Study Group. Rupatadine in the treatment of chronic idiopathic urticaria: A double-blind, randomized, placebo -controlled multicentre study. Allergy, 2007, 62(5), 539-546.
[http://dx.doi.org/10.1111/j.1398-9995.2007.01330.x] [PMID: 17441794]
[37]
Zuberbier, T.; Münzberger, C.; Haustein, U.; Trippas, E.; Burtin, B.; Mariz, S.D.; Henz, B.M. Double-blind crossover study of high-dose cetirizine in cholinergic urticaria. Dermatology (Basel), 1996, 193(4), 324-327.
[http://dx.doi.org/10.1159/000246281] [PMID: 8993958]
[38]
Staevska, M.; Popov, T.A.; Kralimarkova, T.; Lazarova, C.; Kraeva, S.; Popova, D.; Church, D.S.; Dimitrov, V.; Church, M.K. The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria. J. Allergy Clin. Immunol., 2010, 125(3), 676-682.
[http://dx.doi.org/10.1016/j.jaci.2009.11.047] [PMID: 20226302]
[39]
Saini, S.; Rosen, K.E.; Hsieh, H.J.; Wong, D.A.; Conner, E.; Kaplan, A.; Spector, S.; Maurer, M. A randomized, placebo -controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. J. Allergy Clin. Immunol., 2011, 128(3), 567-73.e1.
[http://dx.doi.org/10.1016/j.jaci.2011.06.010] [PMID: 21762974]
[40]
Maurer, M.; Altrichter, S.; Bieber, T.; Biedermann, T.; Bräutigam, M.; Seyfried, S.; Brehler, R.; Grabbe, J.; Hunzelmann, N.; Jakob, T.; Jung, A.; Kleine-Tebbe, J.; Mempel, M.; Meurer, M.; Reich, K.; Ruëff, F.; Schäkel, K.; Sengupta, K.; Sieder, C.; Simon, J.C.; Wedi, B.; Zuberbier, T.; Mahler, V.; Staubach, P. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. J. Allergy Clin. Immunol., 2011, 128(1), 202-209.e5.
[http://dx.doi.org/10.1016/j.jaci.2011.04.038] [PMID: 21636116]
[41]
Saini, S.S.; Bindslev-Jensen, C.; Maurer, M.; Grob, J.J.; Bülbül Baskan, E.; Bradley, M.S.; Canvin, J.; Rahmaoui, A.; Georgiou, P.; Alpan, O.; Spector, S.; Rosén, K. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: A randomized, placebo -controlled study. J. Invest. Dermatol., 2015, 135(1), 67-75.
[http://dx.doi.org/10.1038/jid.2014.306] [PMID: 25046337]
[42]
Maurer, M.; Rosén, K.; Hsieh, H.J.; Saini, S.; Grattan, C.; Gimenéz-Arnau, A.; Agarwal, S.; Doyle, R.; Canvin, J.; Kaplan, A.; Casale, T. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N. Engl. J. Med., 2013, 368(10), 924-935.
[http://dx.doi.org/10.1056/NEJMoa1215372] [PMID: 23432142]
[43]
Grattan, C.E.; O’Donnell, B.F.; Francis, D.M.; Niimi, N.; Barlow, R.J.; Seed, P.T.; Kobza Black, A.; Greaves, M.W. Randomized double-blind study of cyclosporin in chronic ‘idiopathic’ urticaria. Br. J. Dermatol., 2000, 143(2), 365-372.
[http://dx.doi.org/10.1046/j.1365-2133.2000.03664.x] [PMID: 10951147]
[44]
Vena, G.A.; Cassano, N.; Colombo, D.; Peruzzi, E.; Pigatto, P. Neo-I-30 Study Group. Cyclosporine in chronic idiopathic urticaria: A double-blind, randomized, placebo -controlled trial. J. Am. Acad. Dermatol., 2006, 55(4), 705-709.
[http://dx.doi.org/10.1016/j.jaad.2006.04.078] [PMID: 17010756]
[45]
Kulthanan, K.; Chaweekulrat, P.; Komoltri, C. Cyclosporine for chronic spontaneous urticaria: A meta-analysis and systematic review. J. Allergy Clin. Immunol. Pract., 2018, 6(2), 586-599.
[http://dx.doi.org/10.1016/j.jaip.2017.07.017] [PMID: 28916431]
[46]
Asero, R.; Tedeschi, A. Usefulness of a short course of oral prednisone in antihistamine-resistant chronic urticaria: A retrospective analysis. J. Investig. Allergol. Clin. Immunol., 2010, 20(5), 386-390.
[PMID: 20945604]
[47]
Kaplan, A.; Ledford, D.; Ashby, M.; Canvin, J.; Zazzali, J.L.; Conner, E.; Veith, J.; Kamath, N.; Staubach, P.; Jakob, T.; Stirling, R.G.; Kuna, P.; Berger, W.; Maurer, M.; Rosén, K. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J. Allergy Clin. Immunol., 2013, 132(1), 101-109.
[http://dx.doi.org/10.1016/j.jaci.2013.05.013] [PMID: 23810097]
[48]
Yalcin, A.D. Advances in anti-IgE therapy. BioMed Res. Int., 2015, 2015317465
[http://dx.doi.org/10.1155/2015/317465] [PMID: 26075226]
[49]
Tonacci, A.; Billeci, L.; Pioggia, G.; Navarra, M.; Gangemi, S. Omalizumab for the treatment of chronic idiopathic urticaria: Systematic review of the literature. Pharmacotherapy, 2017, 37(4), 464-480.
[http://dx.doi.org/10.1002/phar.1915] [PMID: 28226418]
[50]
Damiani, G.; Diani, M.; Conic, R.R.Z.; Colli, L.; Ferrucci, S.; Martina, E.; Offidani, A.M.; Pigatto, P.D.M. Omalizumab in chronic urticaria: An Italian survey. Int. Arch. Allergy Immunol., 2019, 178(1), 45-49.
[http://dx.doi.org/10.1159/000492532] [PMID: 30396176]
[51]
Kaplan, A.; Ferrer, M.; Bernstein, J.A.; Antonova, E.; Trzaskoma, B.; Raimundo, K.; Rosén, K.; Omachi, T.A.; Khalil, S.; Zazzali, J.L. Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria. J. Allergy Clin. Immunol., 2016, 137(2), 474-481.
[http://dx.doi.org/10.1016/j.jaci.2015.08.023] [PMID: 26483177]
[52]
Marzano, A.V.; Genovese, G.; Casazza, G.; Fierro, M.T.; Dapavo, P.; Crimi, N.; Ferrucci, S.; Pepe, P.; Liberati, S.; Pigatto, P.D.; Offidani, A.; Martina, E.; Girolomoni, G.; Rovaris, M.; Foti, C.; Stingeni, L.; Cristaudo, A.; Canonica, G.W.; Nettis, E.; Asero, R. Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: A study of 470 patients. J. Eur. Acad. Dermatol. Venereol., 2019, 33(5), 918-924.
[http://dx.doi.org/10.1111/jdv.15350] [PMID: 30451325]
[53]
Ertas, R.; Ozyurt, K.; Atasoy, M.; Hawro, T.; Maurer, M. The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change. Allergy, 2018, 73(3), 705-712.
[http://dx.doi.org/10.1111/all.13345] [PMID: 29083482]
[54]
Asero, R. Chronic spontaneous urticaria treated with Omalizumab: What differentiates early from late responders? Eur. Ann. Allergy Clin. Immunol., 2020.
[http://dx.doi.org/10.23822/EurAnnACI.1764-1489.147] [PMID: 32378398]
[55]
Asero, R.; Ferrucci, S.; Casazza, G.; Marzano, A.V.; Cugno, M. Total IgE and atopic status in patients with severe chronic spontaneous urticaria unresponsive to omalizumab treatment. Allergy, 2019, 74(8), 1561-1563.
[http://dx.doi.org/10.1111/all.13754] [PMID: 30801715]
[56]
Ertas, R.; Ozyurt, K.; Ozlu, E.; Ulas, Y.; Avci, A.; Atasoy, M.; Hawro, T.; Maurer, M. Increased IgE levels are linked to faster relapse in patients with omalizumab-discontinued chronic spontaneous urticaria. J. Allergy Clin. Immunol., 2017, 140(6), 1749-1751.
[http://dx.doi.org/10.1016/j.jaci.2017.08.007] [PMID: 28870460]
[57]
Asero, R.; Marzano, A.V.; Ferrucci, S.; Cugno, M. D-Dimer plasma levels parallel the clinical response to omalizumab in patients with severe chronic spontaneous urticaria. Int. Arch. Allergy Immunol., 2017, 172(1), 40-44.
[http://dx.doi.org/10.1159/000453453] [PMID: 28219067]
[58]
Asero, R.; Marzano, A.V.; Ferrucci, S.; Genovese, G.; Cugno, M. Baseline D-dimer plasma levels correlate with disease activity but not with the response to omalizumab in chronic spontaneous urticaria. Allergy, 2019, 74(12), 2538.
[http://dx.doi.org/10.1111/all.13936] [PMID: 31165493]
[59]
Vadasz, Z.; Tal, Y.; Rotem, M.; Shichter-Confino, V.; Mahlab-Guri, K.; Graif, Y.; Kessel, A.; Agmon-Levin, N.; Maoz-Segal, R.; Kivity, S.; Benor, S.; Lachover-Roth, I.; Zeldin, Y.; Stein, M.; Toker, O.; Hassoun, G.; Bezalel-Rosenberg, S.; Toubi, E.; Asher, I.; Sthoeger, Z. Israeli Forum for investigating and treating Chronic Spontaneous Urticaria (CSU). Omalizumab for severe chronic spontaneous urticaria: Real-life experiences of 280 patients. J. Allergy Clin. Immunol. Pract., 2017, 5(6), 1743-1745.
[http://dx.doi.org/10.1016/j.jaip.2017.08.035] [PMID: 28988786]
[60]
Alizadeh Aghdam, M.; Knol, E.F.; van den Elzen, M.; den Hartog Jager, C.; van Os-Medendorp, H.; Knulst, A.C.; Otten, H.G.; Röckmann, H. Response of FcεRI-bearing leucocytes to omalizumab in chronic spontaneous urticaria. Clin. Exp. Allergy, 2020, 50(3), 364-371.
[http://dx.doi.org/10.1111/cea.13566] [PMID: 31925825]
[61]
Macglashan, D.W., Jr; Saini, S.S. .Omalizumab increases the intrinsic sensitivity of human basophils to IgE-mediated stimulation. J Allergy Clin. Immunol., 2013, 132(4)906-11.e1, 4..
[http://dx.doi.org/10.1016/j.jaci.2013.04.056] [PMID: 23791510]
[62]
Pinto Gouveia, M.; Gameiro, A.; Pinho, A.; Gonçalo, M. Long-term management of chronic spontaneous urticaria with omalizumab. Clin. Exp. Dermatol., 2017, 42(7), 735-742.
[http://dx.doi.org/10.1111/ced.13173] [PMID: 28649751]
[63]
Asero, R. Efficacy of omalizumab 150 mg/month as a maintenance dose in patients with severe chronic spontaneous urticaria showing a prompt and complete response to the drug. Allergy, 2018, 73(11), 2242-2244.
[http://dx.doi.org/10.1111/all.13549] [PMID: 29989179]
[64]
Golembesky, A.; Cooney, M.; Boev, R.; Schlit, A.F.; Bentz, J.W.G. Safety of cetirizine in pregnancy. J. Obstet. Gynaecol., 2018, 38(7), 940-945.
[http://dx.doi.org/10.1080/01443615.2018.1441271] [PMID: 29565188]
[65]
Church, M.K.; Maurer, M.; Simons, F.E.; Bindslev-Jensen, C.; van Cauwenberge, P.; Bousquet, J.; Holgate, S.T.; Zuberbier, T. Global Allergy and Asthma European Network. Risk of first-generation H(1)-antihistamines: A GA(2)LEN position paper. Allergy, 2010, 65(4), 459-466.
[http://dx.doi.org/10.1111/j.1398-9995.2009.02325.x] [PMID: 20146728]
[66]
Namazy, J.A.; Blais, L.; Andrews, E.B.; Scheuerle, A.E.; Cabana, M.D.; Thorp, J.M.; Umetsu, D.T.; Veith, J.H.; Sun, D.; Kaufman, D.G.; Covington, D.L.; Mukhopadhyay, S.; Fogel, R.B.; Lopez-Leon, S.; Spain, C.V. Pregnancy outcomes in the omalizumab pregnancy registry and a disease-matched comparator cohort. J. Allergy Clin. Immunol., 2019, 145(2), 528-536.e1.
[PMID: 31145939]
[67]
González-Medina, M.; Curto-Barredo, L.; Labrador-Horrillo, M.; Giménez-Arnau, A. Omalizumab use during pregnancy for Chronic Spontaneous Urticaria (CSU): Report of two cases. J. Eur. Acad. Dermatol. Venereol., 2017, 31(5), e245-e246.
[http://dx.doi.org/10.1111/jdv.14034] [PMID: 27868240]
[68]
Ghazanfar, M.N.; Thomsen, S.F. Successful and safe treatment of chronic spontaneous urticaria with omalizumab in a woman during two consecutive pregnancies. Case Rep. Med., 2015, 2015368053
[http://dx.doi.org/10.1155/2015/368053] [PMID: 25705229]
[69]
Cuervo-Pardo, L.; Barcena-Blanch, M.; Radojicic, C. Omalizumab use during pregnancy for CIU: A tertiary care experience. Eur. Ann. Allergy Clin. Immunol., 2016, 48(4), 145-146.
[PMID: 27425170]
[70]
Williams, P.V. Pharmacologic management of chronic urticaria in pediatric patients: The gap between guidelines and practice. Paediatr. Drugs, 2020, 22(1), 21-28.
[http://dx.doi.org/10.1007/s40272-019-00365-3] [PMID: 31858489]
[71]
Nayak, A.S.; Berger, W.E.; LaForce, C.F.; Urdaneta, E.R.; Patel, M.K.; Franklin, K.B.; Wu, M.M. Randomized, placebo -controlled study of cetirizine and loratadine in children with seasonal allergic rhinitis. Allergy Asthma Proc., 2017, 38(3), 222-230.
[http://dx.doi.org/10.2500/aap.2017.38.4050] [PMID: 28441993]
[72]
Papadopoulos, N.G.; Zuberbier, T. The safety and tolerability profile of bilastine for chronic urticaria in children. Clin. Transl. Allergy, 2019, 9, 55.
[http://dx.doi.org/10.1186/s13601-019-0294-3] [PMID: 31660121]
[73]
Rodríguez, M.; Vozmediano, V.; García-Bea, A.; Novák, Z.; Yáñez, A.; Campo, C.; Labeaga, L. Pharmacokinetics and safety of bilastine in children aged 6 to 11 years with allergic rhinoconjunctivitis or chronic urticaria. Eur. J. Pediatr., 2020, 179(5), 801-805.
[http://dx.doi.org/10.1007/s00431-019-03559-6] [PMID: 31919579]
[74]
Fitzsimons, R.; van der Poel, L.A.; Thornhill, W.; du Toit, G.; Shah, N.; Brough, H.A. Antihistamine use in children. Arch. Dis. Child. Educ. Pract. Ed., 2015, 100(3), 122-131.
[http://dx.doi.org/10.1136/archdischild-2013-304446] [PMID: 25147323]
[75]
Al-Shaikhly, T.; Rosenthal, J.A.; Ayars, A.G.; Petroni, D.H. Omalizumab for chronic urticaria in children younger than 12 years. Ann. Allergy Asthma Immunol., 2019, 123(2), 208-210.e2.
[http://dx.doi.org/10.1016/j.anai.2019.05.003] [PMID: 31082483]
[76]
Leonardi, L.; Uva, A.; Duse, M. Chronic urticaria in a child affected by atopic dermatitis: Effective treatment with omalizumab. J. Dermatolog. Treat., 2018, 29(3), 17-19.
[77]
Crisafulli, G.; Caminiti, L.; Chiera, F.; Arasi, S.; Salzano, G.; Panasiti, I.; Barbalace, A.; Pajno, G.B. Omalizumab in children with severe allergic disease: A case series. Ital. J. Pediatr., 2019, 45(1), 13.
[http://dx.doi.org/10.1186/s13052-019-0602-5] [PMID: 30642367]
[78]
Vollono, L.; Piccolo, A.; Lanna, C.; Esposito, M.; Bavetta, M.; Campione, E.; Bianchi, L.; Diluvio, L. Omalizumab for chronic spontaneous urticaria in “complex” patients: Data from real-life clinical practice. Drug Des. Devel. Ther., 2019, 13, 3181-3186.
[http://dx.doi.org/10.2147/DDDT.S214307] [PMID: 31564834]
[79]
Antonicelli, L.; Stagnozzi, G.; Giuliodoro, S.; Abbruzzetti, A.; Massaccesi, C. The safety of omalizumab therapy in a patient with severe persistent allergic asthma and hepatitis C. Ann. Allergy Asthma Immunol., 2009, 103(3), 269-270.
[http://dx.doi.org/10.1016/S1081-1206(10)60194-9] [PMID: 19788028]
[80]
Chicharro, P.; Rodríguez-Jiménez, P.; de Argila, D. Efficacy and safety of omalizumab in a patient with chronic spontaneous urticaria and active hepatitis B virus infection. Actas Dermosifiliogr., 2017, 108(4), 383-384.
[http://dx.doi.org/10.1016/j.adengl.2017.03.010] [PMID: 27914623]
[81]
Leiva-Salinas, M.; Francés, L.; Marin-Cabanas, I.; Arribas Granados, M.P.; Silvestre, J.F. Effectiveness and safety of omalizumab in a patient with chronic urticaria and hepatitis C. J. Eur. Acad. Dermatol. Venereol., 2015, 29(5), 1027-1028.
[http://dx.doi.org/10.1111/jdv.12450] [PMID: 24629127]
[82]
Long, A.; Rahmaoui, A.; Rothman, K.J.; Guinan, E.; Eisner, M.; Bradley, M.S.; Iribarren, C.; Chen, H.; Carrigan, G.; Rosén, K.; Szefler, S.J. Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab. J. Allergy Clin. Immunol., 2014, 134(3), 560-567.e4.
[http://dx.doi.org/10.1016/j.jaci.2014.02.007] [PMID: 24679845]
[83]
Iemoli, E.; Niero, F.; Borgonovo, L.; Cossu, M.V.; Piconi, S. Successful Omalizumab treatment in HIV positive patient with chronic spontaneous urticaria: A case report. Eur. Ann. Allergy Clin. Immunol., 2017, 49(2), 88-91.
[PMID: 28294590]
[84]
Arm, J.P.; Bottoli, I.; Skerjanec, A.; Floch, D.; Groenewegen, A.; Maahs, S.; Owen, C.E.; Jones, I.; Lowe, P.J. Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects. Clin. Exp. Allergy, 2014, 44(11), 1371-1385.
[http://dx.doi.org/10.1111/cea.12400] [PMID: 25200415]
[85]
Gauvreau, G.M.; Arm, J.P.; Boulet, L.P.; Leigh, R.; Cockcroft, D.W.; Davis, B.E.; Mayers, I.; FitzGerald, J.M.; Dahlen, B.; Killian, K.J.; Laviolette, M.; Carlsten, C.; Lazarinis, N.; Watson, R.M.; Milot, J.; Swystun, V.; Bowen, M.; Hui, L.; Lantz, A.S.; Meiser, K.; Maahs, S.; Lowe, P.J.; Skerjanec, A.; Drollmann, A.; O’Byrne, P.M. Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responses. J. Allergy Clin. Immunol., 2016, 138(4), 1051-1059.
[http://dx.doi.org/10.1016/j.jaci.2016.02.027] [PMID: 27185571]
[86]
Maurer, M.; Giménez-Arnau, A.M.; Sussman, G.; Metz, M.; Baker, D.R.; Bauer, A.; Bernstein, J.A.; Brehler, R.; Chu, C.Y.; Chung, W.H.; Danilycheva, I.; Grattan, C.; Hébert, J.; Katelaris, C.; Makris, M.; Meshkova, R.; Savic, S.; Sinclair, R.; Sitz, K.; Staubach, P.; Wedi, B.; Löffler, J.; Barve, A.; Kobayashi, K.; Hua, E.; Severin, T.; Janocha, R. Ligelizumab for chronic spontaneous urticaria. N. Engl. J. Med., 2019, 381(14), 1321-1332.
[http://dx.doi.org/10.1056/NEJMoa1900408] [PMID: 31577874]
[87]
Gauvreau, G.M.; Harris, J.M.; Boulet, L.P.; Scheerens, H.; Fitzgerald, J.M.; Putnam, W.S.; Cockcroft, D.W.; Davis, B.E.; Leigh, R.; Zheng, Y.; Dahlén, B.; Wang, Y.; Maciuca, R.; Mayers, I.; Liao, X.C.; Wu, L.C.; Matthews, J.G.; O’Byrne, P.M. Targeting membrane-expressed IgE B cell receptor with an antibody to the M1 prime epitope reduces IgE production. Sci. Transl. Med., 2014, 6(243)243ra85
[http://dx.doi.org/10.1126/scitranslmed.3008961] [PMID: 24990880]
[88]
Harris, J.M.; Maciuca, R.; Bradley, M.S.; Cabanski, C.R.; Scheerens, H.; Lim, J.; Cai, F.; Kishnani, M.; Liao, X.C.; Samineni, D.; Zhu, R.; Cochran, C.; Soong, W.; Diaz, J.D.; Perin, P.; Tsukayama, M.; Dimov, D.; Agache, I.; Kelsen, S.G. A randomized trial of the efficacy and safety of quilizumab in adults with inadequately controlled allergic asthma. Respir. Res., 2016, 17, 29.
[http://dx.doi.org/10.1186/s12931-016-0347-2] [PMID: 26993628]
[89]
Harris, J.M.; Cabanski, C.R.; Scheerens, H.; Samineni, D.; Bradley, M.S.; Cochran, C.; Staubach, P.; Metz, M.; Sussman, G.; Maurer, M. A randomized trial of quilizumab in adults with refractory chronic spontaneous urticaria. J. Allergy Clin. Immunol., 2016, 138(6), 1730-1732.
[http://dx.doi.org/10.1016/j.jaci.2016.06.023] [PMID: 27567329]
[90]
Magerl, M.; Philipp, S.; Manasterski, M.; Friedrich, M.; Maurer, M. Successful treatment of delayed pressure urticaria with anti-TNF-alpha. J. Allergy Clin. Immunol., 2007, 119(3), 752-754.
[http://dx.doi.org/10.1016/j.jaci.2006.12.658] [PMID: 17336621]
[91]
Wilson, L.H.; Eliason, M.J.; Leiferman, K.M.; Hull, C.M.; Powell, D.L. Treatment of refractory chronic urticaria with tumor necrosis factor-alfa inhibitors. J. Am. Acad. Dermatol., 2011, 64(6), 1221-1222.
[http://dx.doi.org/10.1016/j.jaad.2009.10.043] [PMID: 21571206]
[92]
Sand, F.L.; Thomsen, S.F. TNF-alpha inhibitors for chronic urticaria: Experience in 20 patients. J. Allergy (Cairo), 2013, 2013130905
[http://dx.doi.org/10.1155/2013/130905] [PMID: 24167521]
[93]
Trinh, H.K.; Pham, D.L.; Ban, G.Y.; Lee, H.Y.; Park, H.S.; Ye, Y.M. Altered systemic adipokines in patients with chronic urticaria. Int. Arch. Allergy Immunol., 2016, 171(2), 102-110.https://www.karger.com/Article/FullText/452626
[PMID: 27902979]
[94]
Fougerousse, A.C.; Becherel, P.A.; Pallure, V.; Boyé, T.; Reguiai, Z.; Gabison, G.; Barthelemy, H.; Badaoui, A.; Mahé, E.; Livideanu, C.B. GEM ResoPso. Combining omalizumab with another biotherapy. Acta Derm. Venereol., 2019, 99(4), 448-449.
[http://dx.doi.org/10.2340/00015555-3140] [PMID: 30723874]
[95]
Cooke, A.; Bulkhi, A.; Casale, T.B. Role of biologics in intractable urticaria. Biologics, 2015, 9, 25-33.
[PMID: 25926715]
[96]
Combalia, A.; Losno, R.A.; Prieto-González, S.; Mascaró, J.M. Rituximab in refractory chronic spontaneous urticaria: An encouraging therapeutic approach. Skin Pharmacol. Physiol., 2018, 31(4), 184-187.
[http://dx.doi.org/10.1159/000487402] [PMID: 29649806]
[97]
Steinweg, S.A.; Gaspari, A.A. Rituximab for the treatment of recalcitrant chronic autoimmune urticaria. J. Drugs Dermatol., 2015, 14(12), 1387.
[PMID: 26659929]
[98]
Saigal, K.; Valencia, I.C.; Cohen, J.; Kerdel, F.A. Hypocomplementemic urticarial vasculitis with angioedema, a rare presentation of systemic lupus erythematosus: Rapid response to rituximab. J. Am. Acad. Dermatol., 2003, 49(5)(Suppl.), S283-S285.
[http://dx.doi.org/10.1016/S0190-9622(03)00744-8] [PMID: 14576655]
[99]
Busse, P.J.; Gernez, Y. Clinical and biological response to rituximab treatment in 3 patients with acquired C1-inhibitor deficiency. Ann. Allergy Asthma Immunol., 2017, 119(4), 380-382.
[http://dx.doi.org/10.1016/j.anai.2017.07.032] [PMID: 28866304]
[100]
Vena, G.A.; Maurer, M.; Cassano, N.; Zuberbier, T. Alternative treatments for chronic spontaneous urticaria beyond the guideline algorithm. Curr. Opin. Allergy Clin. Immunol., 2017, 17(4), 278-285.
[http://dx.doi.org/10.1097/ACI.0000000000000372] [PMID: 28537934]
[101]
Nham, T.; Saleh, C.; Chu, D.; Vakaljan, S.L.; Ohayon, J.A.; Siegal, D.M. Refractory urticaria and the importance of diagnosing Schnitzler’s syndrome. BMJ Case Rep., 2019, 12(4)e228546
[http://dx.doi.org/10.1136/bcr-2018-228546] [PMID: 31036740]
[102]
Hidalgo-García, Y.; García-Fernández, E.; Palacio-Aller, L.; Gonzalvo, P. Schnitzler syndrome with response to anakinra monotherapy: 7 years of follow-up. Actas Dermosifiliogr., 2017, 108(10), 956-958.
[http://dx.doi.org/10.1016/j.adengl.2017.10.022] [PMID: 28728792]
[103]
Sönnichsen, A.; Saulite, I.; Mangana, J.; Kerl, K.; Mehra, T.; Desislava, I.; Chang, Y.T.; Petrausch, U.; Schmid-Grendelmeier, P.; Hoetzenecker, W.; Cozzio, A.; Guenova, E. Interleukin-1 receptor antagonist (anakinra) for Schnitzler syndrome. J. Dermatolog. Treat., 2016, 27(5), 436-438.
[http://dx.doi.org/10.3109/09546634.2015.1136048] [PMID: 26864191]
[104]
Bashir, M.; Bettendorf, B.; Hariman, R. A rare but fascinating disorder: Case collection of patients with schnitzler syndrome. Case Rep. Rheumatol., 2018, 20187041576
[http://dx.doi.org/10.1155/2018/7041576] [PMID: 29707401]
[105]
Krause, K.; Weller, K.; Stefaniak, R.; Wittkowski, H.; Altrichter, S.; Siebenhaar, F.; Zuberbier, T.; Maurer, M. Efficacy and safety of the interleukin-1 antagonist rilonacept in Schnitzler syndrome: an open-label study. Allergy, 2012, 67(7), 943-950.
[http://dx.doi.org/10.1111/j.1398-9995.2012.02843.x] [PMID: 22583335]
[106]
Kolivras, A.; Theunis, A.; Ferster, A.; Lipsker, D.; Sass, U.; Dussart, A.; André, J. Cryopyrin-associated periodic syndrome: an autoinflammatory disease manifested as neutrophilic urticarial dermatosis with additional perieccrine involvement. J. Cutan. Pathol., 2011, 38(2), 202-208.
[http://dx.doi.org/10.1111/j.1600-0560.2010.01638.x] [PMID: 21062341]
[107]
Kapoor, S. The rapidly evolving role of anakinra in dermatology: A double-edged sword. J. Am. Acad. Dermatol., 2008, 59(6), 1092-1093.
[http://dx.doi.org/10.1016/j.jaad.2008.08.026] [PMID: 19022112]
[108]
Krause, K.; Mahamed, A.; Weller, K.; Metz, M.; Zuberbier, T.; Maurer, M. Efficacy and safety of canakinumab in urticarial vasculitis: An open-label study. J. Allergy Clin. Immunol., 2013, 132(3), 751-754.e5.
[http://dx.doi.org/10.1016/j.jaci.2013.04.008] [PMID: 23711544]
[109]
Krause, K.; Tsianakas, A.; Wagner, N.; Fischer, J.; Weller, K.; Metz, M.; Church, M.K.; Maurer, M. Efficacy and safety of canakinumab in Schnitzler syndrome: A multicenter randomized placebo -controlled study. J. Allergy Clin. Immunol., 2017, 139(4), 1311-1320.
[http://dx.doi.org/10.1016/j.jaci.2016.07.041] [PMID: 27658762]
[110]
Church, M.K.; Kolkhir, P.; Metz, M.; Maurer, M. The role and relevance of mast cells in urticaria. Immunol. Rev., 2018, 282(1), 232-247.
[http://dx.doi.org/10.1111/imr.12632] [PMID: 29431202]
[111]
Palikhe, N.S.; Kim, S.H.; Ye, Y.M.; Hur, G.Y.; Cho, B.Y.; Park, H.S. Association of CRTH2 gene polymorphisms with the required dose of antihistamines in patients with chronic urticaria. Pharmacogenomics, 2009, 10(3), 375-383.
[http://dx.doi.org/10.2217/14622416.10.3.375] [PMID: 19290788]
[112]
Oliver, E.T.; Chichester, K.; Devine, K.; Sterba, P.M.; Wegner, C.; Vonakis, B.M.; Saini, S.S. Effects of an Oral CRTh2 antagonist (AZD1981) on eosinophil activity and symptoms in chronic spontaneous urticaria. Int. Arch. Allergy Immunol., 2019, 179(1), 21-30.
[http://dx.doi.org/10.1159/000496162] [PMID: 30879003]
[113]
Bateman, E.D.; O’Brien, C.; Rugman, P.; Luke, S.; Ivanov, S.; Uddin, M. Efficacy and safety of the CRTh2 antagonist AZD1981 as add-on therapy to inhaled corticosteroids and long-acting β2-agonists in patients with atopic asthma. Drug Des. Devel. Ther., 2018, 12, 1093-1106.
[http://dx.doi.org/10.2147/DDDT.S147389] [PMID: 29765200]
[114]
Zheng, D.; Yang, X. Clinical observation on the therapeutic effect of desloratadine citrate disodium in the treatment of chronic urticaria and changes in IL4, IL18, IL23 and IL-33 levels before and after treatment. Pak. J. Pharm. Sci., 2017, 30(3 Special), 1139-1142.
[PMID: 28671097]
[115]
Iemoli, E.; Piconi, S.; Fusi, A.; Borgonovo, L.; Borelli, M.; Trabattoni, D. Immunological effects of omalizumab in chronic urticaria: A case report. J. Investig. Allergol. Clin. Immunol., 2010, 20(3), 252-254.
[PMID: 20635791]
[116]
Lee, J.K.; Simpson, R.S. Dupilumab as a novel therapy for difficult to treat chronic spontaneous urticaria. J. Allergy Clin. Immunol. Pract., 2019, 7(5), 1659-1661.e1.
[http://dx.doi.org/10.1016/j.jaip.2018.11.018] [PMID: 30496828]
[117]
Ferrucci, S.; Benzecry, V.; Berti, E.; Asero, R. Rapid disappearance of both severe atopic dermatitis and cold urticaria following dupilumab treatment. Clin. Exp. Dermatol., 2020, 45(3), 345-346.
[http://dx.doi.org/10.1111/ced.14081] [PMID: 31437869]
[118]
Maloney, N.J.; Tegtmeyer, K.; Zhao, J.; Worswick, S. Dupilumab in dermatology: Potential for uses beyond atopic dermatitis. J. Drugs Dermatol., 2019, 18(10)S1545961619P1053X.
[PMID: 31603635]
[119]
Bagnasco, D.; Caminati, M.; Ferrando, M.; Aloè, T.; Testino, E.; Canonica, G.W.; Passalacqua, G. Anti-IL-5 and IL-5Ra: Efficacy and safety of new therapeutic strategies in severe uncontrolled asthma. BioMed Res. Int., 2018, 20185698212
[http://dx.doi.org/10.1155/2018/5698212] [PMID: 30519580]
[120]
Bleecker, E.R.; FitzGerald, J.M.; Chanez, P.; Papi, A.; Weinstein, S.F.; Barker, P.; Sproule, S.; Gilmartin, G.; Aurivillius, M.; Werkström, V.; Goldman, M. SIROCCO study investigators. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): A randomised, multicentre, placebo -controlled phase 3 trial. Lancet, 2016, 388(10056), 2115-2127.
[http://dx.doi.org/10.1016/S0140-6736(16)31324-1] [PMID: 27609408]
[121]
Bergmann, K.C.; Altrichter, S.; Maurer, M. Benefit of benralizumab treatment in a patient with chronic symptomatic dermographism. J. Eur. Acad. Dermatol. Venereol., 2019, 33(11), e413-e415.
[http://dx.doi.org/10.1111/jdv.15720] [PMID: 31140658]
[122]
Magerl, M.; Terhorst, D.; Metz, M.; Altrichter, S.; Zuberbier, T.; Maurer, M.; Bergmann, K.C. Benefit of mepolizumab treatment in a patient with chronic spontaneous urticaria. J. Dtsch. Dermatol. Ges., 2018, 16(4), 477-478.
[http://dx.doi.org/10.1111/ddg.13481] [PMID: 29578281]
[123]
Maurer, M.; Altrichter, S.; Metz, M.; Zuberbier, T.; Church, M.K.; Bergmann, K.C. Benefit from reslizumab treatment in a patient with chronic spontaneous urticaria and cold urticaria. J. Eur. Acad. Dermatol. Venereol., 2018, 32(3), e112-e113.
[http://dx.doi.org/10.1111/jdv.14594] [PMID: 28924988]
[124]
Barker, M.D.; Liddle, J.; Atkinson, F.L.; Wilson, D.M.; Dickson, M.C.; Ramirez-Molina, C.; Lewis, H.; Davis, R.P.; Somers, D.O.; Neu, M.; Jones, E.; Watson, R. Discovery of potent and selective spleen tyrosine kinase inhibitors for the topical treatment of inflammatory skin disease. Bioorg. Med. Chem. Lett., 2018, 28(21), 3458-3462.
[http://dx.doi.org/10.1016/j.bmcl.2018.09.022] [PMID: 30249354]
[125]
Ramirez Molina, C.; Falkencrone, S.; Skov, P.S.; Hooper-Greenhill, E.; Barker, M.; Dickson, M.C. GSK2646264, a spleen tyrosine kinase inhibitor, attenuates the release of histamine in ex vivo human skin. Br. J. Pharmacol., 2019, 176(8), 1135-1142.
[http://dx.doi.org/10.1111/bph.14610] [PMID: 30735243]
[126]
Youngblood, B.A.; Brock, E.C.; Leung, J.; Falahati, R.; Bryce, P.J.; Bright, J.; Williams, J.; Shultz, L.D.; Greiner, D.L.; Brehm, M.A.; Bebbington, C.; Tomasevic, N. AK002, a humanized sialic acid-binding immunoglobulin-like lectin-8 antibody that induces antibody-dependent cell-mediated cytotoxicity against human eosinophils and inhibits mast cell-mediated anaphylaxis in mice. Int. Arch. Allergy Immunol., 2019, 180(2), 91-102.
[http://dx.doi.org/10.1159/000501637] [PMID: 31401630]
[127]
Kelly, V.; Genovese, M. Novel small molecule therapeutics in rheumatoid arthritis. Rheumatology (Oxford), 2013, 52(7), 1155-1162.
[http://dx.doi.org/10.1093/rheumatology/kes367] [PMID: 23297340]
[128]
Advani, R.H.; Buggy, J.J.; Sharman, J.P.; Smith, S.M.; Boyd, T.E.; Grant, B.; Kolibaba, K.S.; Furman, R.R.; Rodriguez, S.; Chang, B.Y.; Sukbuntherng, J.; Izumi, R.; Hamdy, A.; Hedrick, E.; Fowler, N.H. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J. Clin. Oncol., 2013, 31(1), 88-94.
[http://dx.doi.org/10.1200/JCO.2012.42.7906] [PMID: 23045577]
[129]
Jones, N.S.; Yoshida, K.; Salphati, L.; Kenny, J.R.; Durk, M.R.; Chinn, L.W. Complex DDI by fenebrutinib and the use of transporter endogenous biomarkers to elucidate the mechanism of DDI. Clin. Pharmacol. Ther., 2020, 107(1), 269-277.
[http://dx.doi.org/10.1002/cpt.1599] [PMID: 31376152]
[130]
Crawford, J.J.; Johnson, A.R.; Misner, D.L.; Belmont, L.D.; Castanedo, G.; Choy, R.; Coraggio, M.; Dong, L.; Eigenbrot, C.; Erickson, R.; Ghilardi, N.; Hau, J.; Katewa, A.; Kohli, P.B.; Lee, W.; Lubach, J.W.; McKenzie, B.S.; Ortwine, D.F.; Schutt, L.; Tay, S.; Wei, B.; Reif, K.; Liu, L.; Wong, H.; Young, W.B. Discovery of GDC-0853: A potent, selective, and noncovalent Bruton’s tyrosine kinase inhibitor in early clinical development. J. Med. Chem., 2018, 61(6), 2227-2245.
[http://dx.doi.org/10.1021/acs.jmedchem.7b01712] [PMID: 29457982]
[131]
Kolkhir, P.; Altrichter, S.; Munoz, M.; Hawro, T.; Maurer, M. New treatments for chronic urticaria. Ann. Allergy Asthma Immunol., 2020, 124(1), 2-12.
[http://dx.doi.org/10.1016/j.anai.2019.08.014] [PMID: 31446134]
[132]
Fujisawa, D.; Kashiwakura, J.; Kita, H.; Kikukawa, Y.; Fujitani, Y.; Sasaki-Sakamoto, T.; Kuroda, K.; Nunomura, S.; Hayama, K.; Terui, T.; Ra, C.; Okayama, Y. Expression of Mas-related gene X2 on mast cells is upregulated in the skin of patients with severe chronic urticaria. J. Allergy Clin. Immunol., 2014, 134(3), 622-633.e9.
[http://dx.doi.org/10.1016/j.jaci.2014.05.004] [PMID: 24954276]
[133]
Subramanian, H.; Gupta, K.; Ali, H. Roles of Mas-related G protein-coupled receptor X2 on mast cell-mediated host defense, pseudoallergic drug reactions, and chronic inflammatory diseases. J. Allergy Clin. Immunol., 2016, 138(3), 700-710.
[http://dx.doi.org/10.1016/j.jaci.2016.04.051] [PMID: 27448446]
[134]
Thangam, E.B.; Jemima, E.A.; Singh, H.; Baig, M.S.; Khan, M.; Mathias, C.B.; Church, M.K.; Saluja, R. The role of histamine and histamine receptors in mast cell-mediated allergy and inflammation: The hunt for new therapeutic targets. Front. Immunol., 2018, 9, 1873.
[http://dx.doi.org/10.3389/fimmu.2018.01873] [PMID: 30150993]
[135]
Sonkoly, E.; Muller, A.; Lauerma, A.I.; Pivarcsi, A.; Soto, H.; Kemeny, L.; Alenius, H.; Dieu-Nosjean, M.C.; Meller, S.; Rieker, J.; Steinhoff, M.; Hoffmann, T.K.; Ruzicka, T.; Zlotnik, A.; Homey, B. IL-31: A new link between T cells and pruritus in atopic skin inflammation. J. Allergy Clin. Immunol., 2006, 117(2), 411-417.
[http://dx.doi.org/10.1016/j.jaci.2005.10.033] [PMID: 16461142]
[136]
Raap, U.; Wieczorek, D.; Gehring, M.; Pauls, I.; Ständer, S.; Kapp, A.; Wedi, B. Increased levels of serum IL-31 in chronic spontaneous urticaria. Exp. Dermatol., 2010, 19(5), 464-466.
[http://dx.doi.org/10.1111/j.1600-0625.2010.01067.x] [PMID: 20163453]
[137]
Lin, W.; Zhou, Q.; Liu, C.; Ying, M.; Xu, S. Increased plasma IL-17, IL-31, and IL-33 levels in chronic spontaneous urticaria. Sci. Rep., 2017, 7(1), 17797.
[http://dx.doi.org/10.1038/s41598-017-18187-z] [PMID: 29259273]
[138]
Gibbs, B.F.; Patsinakidis, N.; Raap, U. Role of the pruritic cytokine IL-31 in autoimmune skin diseases. Front. Immunol., 2019, 10, 1383.
[http://dx.doi.org/10.3389/fimmu.2019.01383] [PMID: 31281316]
[139]
Silverberg, J.I.; Pinter, A.; Pulka, G.; Poulin, Y.; Bouaziz, J.D.; Wollenberg, A.; Murrell, D.F.; Alexis, A.; Lindsey, L.; Ahmad, F.; Piketty, C.; Clucas, A. Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus. J. Allergy Clin. Immunol., 2020, 145(1), 173-182.
[http://dx.doi.org/10.1016/j.jaci.2019.08.013] [PMID: 31449914]
[140]
Kallmeyer, K.; André-Lévigne, D.; Baquié, M.; Krause, K.H.; Pepper, M.S.; Pittet-Cuénod, B.; Modarressi, A. Fate of systemically and locally administered adipose-derived mesenchymal stromal cells and their effect on wound healing. Stem Cells Transl. Med., 2020, 9(1), 131-144.
[http://dx.doi.org/10.1002/sctm.19-0091] [PMID: 31613054]

Rights & Permissions Print Cite
Article Metrics
109
4
© 2024 Bentham Science Publishers | Privacy Policy